Form D · Biotechnology
Mined Therapeutics, Inc.
Cambridge, MA · CIK 0001884272
Offering snapshot reported Sep 27, 2021 · SEC filing
- Reported sold
- $7M Offering amount: $7M
- Investors reported
- 18 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 15, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 27, 2021 | Initial | $6,999,998 | No comparison | 18 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-414680
Source: Form D, filed Sep 27, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Alex Koglin | Director |
| Thomas Nickoloff | Director |
| Andrew Sandford | Director, Executive |
| David Seldin | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
245 First Street 18 Th Floor
Cambridge, MA, 02142
Cambridge, MA, 02142